Medical case reports suggest that cannabinoids extracted from Cannabis sativa have
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …

Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …

Cannabinoid receptors, endocannabinoids and the enzymes responsible for their
biosynthesis and degradation constitute the endocannabinoid system. In recent decades …

The basal ganglia are subcortical nuclei controlling voluntary actions and have been
implicated in Parkinson's disease (PD). The prevailing model of basal ganglia function …

The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

Parkinson's disease (PD) is a neurodegenerative disease characterized by a progressive
loss of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and …

The recent identification of cannabinoid receptors and their endogenous lipid ligands has
triggered an exponential growth of studies exploring the endocannabinoid system and its …

Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and
other neurological defects. The definite cause of and pathways underlying the progression …

Endocannabinoids are lipid chemical mediators that act locally by activating cannabinoid
receptors of type 1 (CB 1) and type 2 (CB 2) receptors. The two most-studied …

Abstract l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …